4//SEC Filing
GAROFALO ELIZABETH A. 4
Accession 0000950170-24-029542
CIK 0001582313other
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 8:09 PM ET
Size
19.3 KB
Accession
0000950170-24-029542
Insider Transaction Report
Form 4
GAROFALO ELIZABETH A.
Director
Transactions
- Exercise/Conversion
Common Shares
2024-03-08$18.56/sh+3,500$64,960→ 3,500 total - Tax Payment
Common Shares
2024-03-08$46.16/sh−1,408$64,993→ 2,092 total - Sale
Common Shares
2024-03-08$45.69/sh−2,092$95,583→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-08−3,500→ 16,500 totalExercise: $18.56Exp: 2031-06-02→ Common Shares (20,000 underlying)
Footnotes (2)
- [F1]Represents the closing price of the Company's common shares on March 7, 2024 for purposes of net settlement calculations.
- [F2]One-third of the total shares subject to the Option vested on the one year anniversary of the grant date, one-third of the total shares subject to the Option vested on the two year anniversary of the grant date, and one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeother
Related Parties
1- filerCIK 0001826361
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 8:09 PM ET
- Size
- 19.3 KB